Mallinckrodt (NYSE:MNK) announced its quarterly earnings results on Tuesday. The company reported $2.01 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.72 by $0.29, Bloomberg Earnings reports. Mallinckrodt had a net margin of 66.25% and a return on equity of 13.43%. The firm had revenue of $792.30 million for the quarter, compared to analyst estimates of $769.91 million. During the same period last year, the business earned $1.91 EPS. Mallinckrodt’s revenue for the quarter was down 4.5% compared to the same quarter last year. Mallinckrodt updated its FY guidance to $6.00-6.50 EPS.
Mallinckrodt (NYSE:MNK) opened at $16.70 on Thursday. The company has a quick ratio of 1.05, a current ratio of 2.18 and a debt-to-equity ratio of 0.98. The company has a market cap of $1,772.79, a price-to-earnings ratio of 0.74, a price-to-earnings-growth ratio of 0.36 and a beta of 1.04. Mallinckrodt has a one year low of $15.27 and a one year high of $53.12.
A number of hedge funds and other institutional investors have recently bought and sold shares of MNK. Sterling Capital Management LLC acquired a new position in Mallinckrodt in the second quarter valued at $204,000. State Treasurer State of Michigan boosted its holdings in shares of Mallinckrodt by 11.9% in the third quarter. State Treasurer State of Michigan now owns 36,500 shares of the company’s stock valued at $1,364,000 after acquiring an additional 3,888 shares in the last quarter. Nationwide Fund Advisors boosted its holdings in shares of Mallinckrodt by 292.1% in the third quarter. Nationwide Fund Advisors now owns 185,877 shares of the company’s stock valued at $6,946,000 after acquiring an additional 138,472 shares in the last quarter. First Trust Advisors LP boosted its holdings in shares of Mallinckrodt by 33.6% in the third quarter. First Trust Advisors LP now owns 525,045 shares of the company’s stock valued at $19,621,000 after acquiring an additional 132,000 shares in the last quarter. Finally, Aperio Group LLC boosted its holdings in shares of Mallinckrodt by 35.5% in the third quarter. Aperio Group LLC now owns 58,362 shares of the company’s stock valued at $2,181,000 after acquiring an additional 15,301 shares in the last quarter. Institutional investors own 97.38% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Ticker Report and is owned by of Ticker Report. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3231449/mallinckrodt-mnk-announces-quarterly-earnings-results-beats-expectations-by-0-29-eps.html.
Mallinckrodt Company Profile
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.